Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EPS (Weighted Average and Diluted) (2016 - 2025)

Vanda Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at -$2.39 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 2555.56% year-over-year to -$2.39; the TTM value through Dec 2025 reached -$3.74, down 1033.33%, while the annual FY2025 figure was -$3.74, 1033.33% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$2.39 at Vanda Pharmaceuticals, down from -$0.39 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.17 in Q2 2021 and bottomed at -$2.39 in Q4 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.02 (2023), against an average of -$0.17.
  • The largest annual shift saw EPS (Weighted Average and Diluted) soared 1400.0% in 2021 before it crashed 3878.18% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.12 in 2021, then rose by 0.0% to $0.12 in 2022, then tumbled by 141.67% to -$0.05 in 2023, then plummeted by 80.0% to -$0.09 in 2024, then tumbled by 2555.56% to -$2.39 in 2025.
  • Per Business Quant, the three most recent readings for VNDA's EPS (Weighted Average and Diluted) are -$2.39 (Q4 2025), -$0.39 (Q3 2025), and -$0.46 (Q2 2025).